home All News open_in_new Full Article

Bimiralisib, Topical PI3K/mTOR Inhibitor Shows Up To 92% Clearance Rate And Superior Tolerability In Proof

Torqur AG Announced Full Phase 2 Results at EADV Congress 2025 BASEL, Switzerland — Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full Phase 2 proof-of-concept study results of topical bimiralisib gel (2%) for the treatment of actinic keratosis (AK) […]


today 8 h. ago attach_file Other

attach_file Other
attach_file Sport
attach_file Other
attach_file Sport
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Sport
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Other


ID: 579283632
Add Watch Country

arrow_drop_down